Pharming Group (PHARM)

[plumo]

New Data Published On Ruconest’s Protective Effects After Severe Blood Loss

Leiden, The Netherlands, July 02, 2012. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today that recombinant human C1 inhibitor (rhC1INH; RUCONEST®) has been shown to have a protective effect in a preclinical animal model of severe blood loss designed to simulate battlefield injuries.

These results can be found online here and will be published in print in July 2012 in Shock issue 38:1.

Dr Dalle Lucca et al. found that rhC1INH reduced tissue damage in this pig based model of severe hemorrhage, the tissue damage, following hemorrhage, strongly resembles that of ischemia-reperfusion injury (IRI). These findings further suppo rt the application of rhC1INH in the prevention of IRI such as that found after transplantation, myocardial infarction, major vascular surgery and trauma. Pharming and its partners continue to be interested in the broad therapeutic area of IRI and are reviewing several of these indications for potential future clinical development.

This study was funded by the US Army Medical Research and Materiel Command.